Money from Grunenthal, combined with cash on hand, should “allow Acelrx to reach a break-even point” financially, King said, and may also provide leverage with regard to the rest of the pipeline.
Next is ARX-04, a noninvasive, fast-onset sufentanil product for moderate-to-severe acute pain, in such settings as the battlefield and civilian trauma or injury.
“We have coming up very shortly, in the next few days, an end-of-Phase-II meeting with the FDA,” King said. “We remain interested in the Department of Defense providing some support to move that program forward into Phase III, and we’re in dialogue around that idea.”
I know MM plays games and they have ways to minimize damage and secure profits; however, any retail investors like us would be nuts to hold a short position overnight.
and why would she short a stock like this one that has imminent catalysts? Any high level DD would let you know it was due a EU partner and PDUFA data. All phase 3 data good and ready. Plus, rumored to be acquired although I think that one is low percentage of happening at this time. NEvertheless, so many other stocks to short. We have been feeling pain of pps decrease, but no real signs of reason to see the company had big trouble.
oh nooooo!!!!!! i listened to him ;( ,,,,not
yeah there is now an "element" that has a vested interest in causing distraction for a low floater...minnesota have a good one.
How much money are you really making on celebrating a stock trading in an 11 cent range? Apparently you are very anxious about it to spam the boards with that sort of celebration. I guess I will not be seeing you out at nice places any tme soon. Enjoy the Mountain Dew and World of Warcraft online parties this weekend. enjoy